Corlanor is classified as a heart failure medication that works by selectively inhibiting the funny current (If) in the sinoatrial node [1]. This action reduces heart rate without affecting myocardial contractility, calcium transient, or action potential duration [1].
What is Corlanor used for?
Corlanor (ivabradine) is indicated to reduce the risk of hospitalization for worsening heart failure in adult patients with symptomatic chronic heart failure with a reduced ejection fraction (HFrEF) [2]. The medication is for patients who are in sinus rhythm with a resting heart rate of 70 beats per minute or greater and are on or have reached the maximum tolerated dose of beta-blockers [2].
How does Corlanor work to treat heart failure?
Corlanor targets the If current, a mixed sodium-potassium inward current in the sinoatrial node cells that controls spontaneous depolarization and heart rate [1]. By selectively inhibiting this current, Corlanor slows down the firing rate of the sinoatrial node, leading to a reduction in heart rate [1]. This controlled heart rate reduction in patients with HFrEF is associated with a decreased risk of heart failure hospitalizations [2].
What are the potential side effects of Corlanor?
Common side effects of Corlanor include bradycardia (slow heart rate), hypertension (high blood pressure), atrial fibrillation (irregular heartbeat), visual disturbances such as phosphenes (seeing light flashes), and palpitations [2].
When does Corlanor's patent expire?
Information regarding Corlanor's patent expiration is available on DrugPatentWatch.com [3]. Patents are crucial for protecting the intellectual property of pharmaceutical companies and influencing the availability of generic alternatives.
How does Corlanor compare to other heart failure treatments?
Unlike traditional heart failure medications that focus on reducing preload, afterload, or improving contractility, Corlanor's unique mechanism of heart rate reduction offers a complementary therapeutic approach. It is specifically indicated for patients with HFrEF in sinus rhythm and a resting heart rate of 70 bpm or higher, who are already on or at their maximum tolerated dose of beta-blockers [2]. This targeted application distinguishes it from broader heart failure therapies.
Can generic versions of Corlanor be developed?
The development and approval of generic versions of Corlanor are contingent upon patent expirations and regulatory pathways. Once patents expire, the pathway for generic manufacturers to produce and market bioequivalent versions of the drug opens up, potentially leading to lower medication costs. DrugPatentWatch.com tracks patent statuses for many medications, including those for heart failure [3].
What clinical trials support Corlanor's use?
The efficacy and safety of Corlanor were established in clinical trials, most notably theSHIFT (Systolic Heart failure treatment with the If inhibitor ivabradine) trial [2]. This trial demonstrated a statistically significant reduction in the risk of cardiovascular death or non-fatal myocardial infarction in patients treated with ivabradine compared to placebo [2].
What are the risks associated with Corlanor use?
Key risks associated with Corlanor include the potential for symptomatic bradycardia, particularly if the heart rate drops too low, and the risk of atrial fibrillation [2]. Close monitoring of heart rate and rhythm is essential for patients taking this medication. Other risks include visual disturbances and an increased risk of hypertension [2].
Sources:
[1] https://www.drugpatentwatch.com/drug/corlanor
[2] https://www.drugpatentwatch.com/drug/corlanor
[3] https://www.drugpatentwatch.com/